查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2010060

糖尿病治療市場：2026-2032年全球市場預測（依藥物類別、給藥途徑、糖尿病類型、原產國及分銷管道分類）

Diabetes Drugs Market by Drug Class, Route Of Administration, Diabetes Type, Drug Origin, Distribution Channel - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，糖尿病藥物市場價值將達到 774 億美元，到 2026 年將成長至 816.4 億美元，到 2032 年將達到 1,172.5 億美元，複合年成長率為 6.11%。

主要市場統計數據
基準年 2025 774億美元
預計年份：2026年 816.4億美元
預測年份 2032 1172.5億美元
複合年成長率 (%) 6.11%

簡要概述糖尿病治療趨勢的演變，將科學進步、獲取趨勢和商業性需求連結起來。

糖尿病藥物市場正經歷快速變革時期，這主要得益於藥物類別、給藥方式和商業策略的突破性進展。過去幾年，臨床進展重塑了治療模式，而來自患者偏好和支付方的壓力迫使製藥公司不斷創新，以提高藥物的價值、便利性和患者依從性。因此，從生物製藥公司經營團隊到分銷合作夥伴，相關人員都在重新評估優先事項，以平衡臨床療效、實際可及性和成本因素。

科學進步、數位醫療的融合以及供應鏈的韌性如何重塑糖尿病藥物領域的臨床實踐和商業策略？

糖尿病領域正受到多種相互關聯的因素的影響而發生變革，這些因素正在改變研發重點、臨床實踐和商業模式。腸促胰素生物學和胜肽類療法的進步正在重新定義治療流程，拓展治療選擇，並促使現有企業投資下一代分子和給藥技術。同時，數位健康解決方案和遠端監測使得數據驅動的用藥依從性計畫和真實世界數據在影響保險公司承保範圍和指南採納方面發揮著至關重要的作用。

本研究評估了 2025 年關稅調整和貿易政策轉變將如何重塑整個糖尿病價值鏈的採購、定價和供應鏈策略。

2025年貿易和關稅體系的政策調整將為糖尿病生態系統中的製造商、經銷商和付款方帶來新的複雜性，促使他們重新評估採購、定價和庫存策略。關稅調整可能會增加成品和活性藥物成分的採購成本，迫使採購團隊重新評估供應商選擇，實現供應來源多元化，並增加對區域製造合作夥伴的依賴，以降低風險。因此，這些決策會影響與支付方和採購實體之間的合約動態，因為企業需要在確保獲利能力和供應連續性的同時，努力保持價格競爭力。

透過利用多方面的細分洞察，將藥物類別、給藥途徑、患者類型、來源和分銷管道結合起來，我們明確了臨床和商業性重點。

透過識別臨床需求、商業性機會和營運要求之間的交集，細分有助於明確策略規劃。藥物類別包括Amylin類似物、GLP-1受體促效劑、胰島素和口服降血糖藥物（OADs），胰島素可細分為長效和短效兩類。此框架突顯了不同的研發路徑。胜肽類腸促胰島素療法強調藥物的持久性和代謝獲益，而胰島素領域由於其藥物動力學特性，需要獨特的給藥方法和低溫運輸管理。

美洲、歐洲、中東和非洲以及亞太地區的區域趨勢，以及它們各自的准入途徑，正在塑造監管策略和供應選擇。

隨著糖尿病治療在不同醫療生態系統中不斷發展，區域趨勢持續影響競爭策略、監管策略和製造地。在美洲，市場動態強調與支付方的談判、整合式醫療路徑以及在基層醫療和專科醫療機構中採用創新技術。報銷方式和藥品福利管理機構的角色影響處方藥清單和患者准入計劃，從而創造出優先考慮長期療效和成本效益的環境。

領先的糖尿病相關企業如何透過其深厚的科學研究研發管線、策略聯盟和生產整合來重塑其競爭定位和價值提案。

主要企業之間的競爭格局反映了強大的科學研究管線、策略聯盟和生產管理能力的整合。老牌製藥公司持續投資於產品生命週期延長、給藥方式創新和以療效主導的市場定位，以鞏固其高階市場地位。同時，生技公司和專科藥物研發企業則專注於突破性的作用機制和差異化的獲益風險比，以吸引合作夥伴並達成授權協議。

採取切實可行的跨部門策略措施，協調研發重點、供應多元化、支付方合作和數位整合，以確保競爭優勢。

產業領導企業必須推動一系列協調一致的舉措，將技術和政策變革轉化為永續的競爭優勢。首先，企業應使其研發重點與尚未滿足的需求和支付方的證據要求保持一致，投資於能夠證明長期、永續療效和成本節約的終點指標。同時，產品組合經理需要評估服務途徑創新以及與醫療設備的協同效應，這些創新和協同效應能夠顯著提高患者的用藥依從性，並在競爭激烈的治療領域中實現產品差異化。

為了確保實用見解，我們採用透明的混合方法研究途徑，將與專家的初步訪談、二手文獻綜述和基於情境的檢驗相結合。

本研究途徑結合了結構化的原始研究和嚴謹的二手研究，並採用方法論三角驗證調查方法，確保了研究結果的穩健性和實用性。原始資料來源包括對臨床專業人員、供應鏈負責人、銷售主管和支付方的訪談，旨在了解他們對治療方法採納、報銷趨勢和營運重點的前瞻性觀點。這些定性見解與監管文件、同行評審的臨床文獻和公司資訊披露進行交叉比對，以檢驗技術聲明和研發軌跡。

透過對策略挑戰的綜合分析，確保長期定位，這些策略挑戰包括臨床差異化、營運韌性和與支付方的價值一致性。

總而言之，糖尿病治療領域正處於一個轉折點，科學創新、以患者為中心的醫療服務模式和政策趨勢在此交匯，重新定義了競爭和運作的重點。那些能夠整合深度臨床差異化、穩健的供應策略以及與支付方相契合的價值提案的相關人員，將最有可能獲得永續優勢。在報銷額度有限的環境下，對真實世界證據和患者體驗的雙重關注，對於決定哪些治療方法能夠獲得廣泛應用和優先推廣至關重要。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 糖尿病治療市場：依藥物類別分類

  • Amylin類似物
  • GLP-1受體促效劑
  • 胰島素
    • 長效型
    • 快速起效
  • 口服降血糖藥（OADs）

第9章：糖尿病治療市場：依給藥途徑分類

  • 吸入
  • 注射藥物
  • 口服

第10章 糖尿病治療市場：依糖尿病類型分類

  • 1型糖尿病
  • 2型糖尿病

第11章 糖尿病治療市場：依藥物來源分類

  • 品牌藥品
  • 學名藥

第12章 糖尿病藥物市場：依分銷管道分類

  • 家庭醫療保健
  • 醫院藥房
  • 網路藥房
  • 零售藥房

第13章 糖尿病藥物市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章 糖尿病藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 糖尿病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國糖尿病治療市場

第17章：中國糖尿病治療藥物市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Astellas Pharma Inc
  • AstraZeneca plc
  • Bayer AG
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Cipla Limited
  • Daiichi Sankyo Company Limited
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Johnson and Johnson
  • Merck and Co Inc
  • Novartis AG
  • Novo Nordisk AS
  • Pfizer Inc
  • Roche Holding AG
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd
Product Code: MRR-434CCDA051C3

The Diabetes Drugs Market was valued at USD 77.40 billion in 2025 and is projected to grow to USD 81.64 billion in 2026, with a CAGR of 6.11%, reaching USD 117.25 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 77.40 billion
Estimated Year [2026] USD 81.64 billion
Forecast Year [2032] USD 117.25 billion
CAGR (%) 6.11%

A succinct orientation to the evolving diabetes therapeutics landscape that connects scientific advances, access dynamics, and commercial imperatives

The diabetes therapeutics landscape is experiencing a period of concentrated evolution driven by breakthroughs in drug classes, delivery modalities, and commercial strategies. Over the past several years clinical advances have reshaped treatment paradigms, while patient preferences and payer pressures have simultaneously driven manufacturers to innovate on value, convenience, and adherence. As a result, stakeholders from biopharma executives to distribution partners are recalibrating priorities to reconcile clinical effectiveness with practical access and cost considerations.

This introduction situates readers within the broader context of these converging forces. It emphasizes the interplay between therapeutic innovation and structural shifts in supply chains and reimbursement. The narrative that follows explores transformative shifts across science and commercialization, assesses policy impacts such as tariff changes with cross-border implications, and translates segmentation and regional dynamics into practical insights for leaders. The goal is to provide an integrated, evidence-based foundation for strategy development that aligns scientific opportunity with operational and commercial realities.

How converging scientific advances, digital health integration, and supply chain resilience are reshaping clinical practice and commercial strategies across diabetes therapeutics

The diabetes landscape is being transformed by several interdependent forces that are altering development priorities, clinical practice, and commercial models. Advances in incretin biology and peptide therapeutics have redefined treatment algorithms and expanded the therapeutic toolkit, prompting incumbents to invest in next-generation molecules and delivery technologies. Concurrently, digital health solutions and remote monitoring have elevated the role of data-driven adherence programs and real-world evidence in shaping payer coverage and guideline adoption.

Supply chain resilience and regional manufacturing investments are increasingly strategic priorities, with companies re-evaluating sourcing footprints to reduce exposure to disruptions. Strategic collaborations and platform licensing deals are accelerating, enabling smaller innovators to scale without extensive capital outlay while allowing larger players to broaden their pipelines. These shifts heighten competition but also create windows for differentiation through patient-centric delivery formats, integrated care models, and differentiated value propositions focused on long-term outcomes rather than episodic interventions.

Assessing how recent tariff adjustments and trade policy shifts in 2025 have reconfigured sourcing, pricing, and supply chain strategies across the diabetes value chain

Policy shifts in trade and tariff regimes in 2025 have introduced new complexities for manufacturers, distributors, and payers in the diabetes ecosystem, prompting reappraisals of sourcing, pricing, and inventory strategies. Tariff adjustments can elevate landed costs for finished formulations and active pharmaceutical ingredients, prompting procurement teams to revisit supplier selection, diversify supply bases, and increase reliance on regional manufacturing partners to mitigate exposure. In turn, these decisions influence contracting dynamics with payers and procurement bodies as firms aim to preserve price competitiveness while protecting margin and supply continuity.

Beyond direct cost effects, tariff-driven supply chain responses can accelerate local invest-ment in manufacturing capacity, influencing long-term competitive positioning. Regulatory compliance, customs clearance timelines, and documentation requirements have become focal areas for supply chain teams, as delays can propagate downstream to hospital pharmacies and outpatient access points. Companies that proactively model tariff scenarios and implement flexible sourcing, multi-origin procurement strategies, and near-shore manufacturing options will be better positioned to absorb policy shocks and sustain market access across geographies.

Multidimensional segmentation insights that align drug class, administration route, patient type, origin, and distribution channel to prioritize clinical and commercial priorities

Segmentation drives clarity in strategic planning by revealing where clinical need, commercial opportunity, and operational requirements intersect. Based on Drug Class, the landscape includes Amylin Analogs, GLP-1 Receptor Agonists, Insulin, and Oral Antidiabetic Drugs (OADs), with Insulin further delineated into Long Acting and Short-Acting categories. This framing highlights divergent development pathways: peptide-based incretin therapies emphasize durability and metabolic benefits, whereas insulin segments require differentiated delivery and cold-chain considerations tied to formulation kinetics.

Based on Route Of Administration, therapies span Inhalation, Injectable, and Oral formats, each carrying distinct adherence profiles, device development imperatives, and regulatory pathways. Delivery route choices drive patient experience and real-world persistence, and therefore directly influence positioning and reimbursement conversations. Based on Diabetes Type, the pipeline and product mix serve both Type 1 Diabetes and Type 2 Diabetes populations; clinical needs and care settings vary substantially between these cohorts, necessitating tailored engagement strategies for providers and payers.

Based on Drug Origin, offerings are categorized as Branded Drugs and Generic Drugs, a distinction that affects lifecycle management, price sensitivity, and competitive dynamics. Branded innovators focus on differentiation through outcomes and ancillary services, while generic entrants concentrate on cost leadership and supply continuity. Based on Distribution Channel, products reach patients through Home Healthcare, Hospital Pharmacy, Online Pharmacy, and Retail Pharmacy routes, and each channel imposes unique logistics, reimbursement, and patient education requirements. When these segmentation lenses are combined, they create a multi-dimensional view of opportunity and risk that supports prioritization of assets, channel strategies, and investment decisions.

Regional dynamics and differentiated access pathways across the Americas, Europe Middle East & Africa, and Asia-Pacific that determine regulatory strategy and supply choices

Regional dynamics continue to shape competitive agendas, regulatory strategies, and manufacturing footprints as diabetes care evolves across diverse healthcare ecosystems. In the Americas, market dynamics emphasize payer negotiations, integrated care pathways, and innovation adoption in both primary care and specialist settings. Reimbursement approaches and the role of pharmacy benefit managers impact formulary positioning and patient access programs, creating an environment where evidence of long-term outcomes and cost-effectiveness can unlock preferential placement.

The Europe, Middle East & Africa region offers heterogenous regulatory landscapes and procurement models, with some countries emphasizing centralized tendering and others relying on decentralized reimbursement decisions. This diversity requires tailored regulatory strategies, localized evidence packages, and flexible pricing models to navigate public procurement, hospital purchasing, and national health system priorities. Similarly, Asia-Pacific presents a mix of high-growth demand centers, price-sensitive markets, and rapidly expanding domestic manufacturing capability. Local production and regulatory endorsement can significantly accelerate market entry, while cross-border trade policies and regional partnerships influence supply chain resilience and competitive dynamics. Across all regions, the interplay between local regulation, payer structure, and manufacturing location informs go-to-market sequencing and long-term investment choices.

How scientific pipeline depth, strategic alliances, and manufacturing integration are reshaping competitive positions and value propositions among leading diabetes players

Competitive dynamics among leading companies reflect a blend of deep scientific pipelines, strategic alliances, and manufacturing control. Established pharmaceutical firms continue to invest in lifecycle extensions, delivery innovations, and outcome-driven positioning to protect premium segments. Meanwhile, biotech players and specialty developers focus on breakthrough mechanisms and differentiated benefit-risk profiles that attract partnership interest and licensing arrangements.

Across the sector, companies are prioritizing vertical integration for critical components such as peptide synthesis and cold-chain logistics to reduce exposure to supply disruptions. Strategic alliances frequently couple small-molecule or biologic innovators with larger commercialization partners to accelerate scale and market access. Additionally, the rise of biosimilars and generics in key insulin segments has intensified competition on price and supply security, prompting incumbent companies to emphasize service-based differentiation, patient support programs, and bundled care solutions to sustain brand value.

Practical, cross-functional strategic moves that align R&D priorities, supply diversification, payer engagement, and digital integration to secure competitive advantage

Industry leaders must pursue a coordinated set of actions to translate technological and policy shifts into sustainable advantage. First, companies should align R&D priorities with unmet clinical needs and payer evidence requirements, investing in endpoints that demonstrate durable outcomes and cost offsets over time. In parallel, portfolio managers should evaluate route-of-administration innovations and device synergies that can meaningfully enhance adherence and differentiate offerings in crowded therapeutic classes.

Operationally, firms need to diversify sourcing and accelerate regional manufacturing capabilities to hedge against tariff and trade volatility while shortening lead times for critical ingredients. Commercial teams should deepen engagement with payers and health systems to co-design value agreements and outcomes-based contracts that reflect real-world performance. Moreover, cross-functional investments in digital adherence platforms and remote monitoring should be scaled to support clinical claims with real-world data and strengthen patient retention. Finally, organizations should pursue selective partnerships and licensing arrangements to access complementary capabilities rapidly, balancing internal development with external innovation to maintain agility.

A transparent mixed-methods research approach integrating expert primary interviews, secondary literature review, and scenario-based triangulation to ensure actionable insights

The research approach combines structured primary research with rigorous secondary analysis and methodological triangulation to ensure robustness and practical relevance. Primary inputs included interviews with clinical experts, supply chain leaders, commercial executives, and payers to capture forward-looking perspectives on therapeutic adoption, reimbursement dynamics, and operational priorities. These qualitative insights were triangulated with regulatory filings, peer-reviewed clinical literature, and company disclosures to validate technical claims and development trajectories.

Data synthesis employed scenario analysis to test supply chain and policy sensitivities, while thematic coding distilled recurring strategic imperatives across stakeholders. Quality controls included cross-validation of interview findings with public filings and expert peer review to mitigate bias. Limitations include variability in regional reporting standards and the evolving nature of policy environments; the methodology addresses these by emphasizing scenario-based guidance rather than prescriptive numeric forecasts and by documenting assumptions that underpin strategic implications.

Concluding synthesis of strategic imperatives that combine clinical differentiation, operational resilience, and payer-aligned value to secure long-term positioning

In summary, the diabetes therapeutics domain is at an inflection point where scientific innovation, patient-centered delivery, and policy dynamics intersect to redefine competitive and operational priorities. Stakeholders who integrate deep clinical differentiation with resilient supply strategies and payer-aligned value propositions will be best positioned to capture sustainable advantages. The dual focus on real-world evidence and patient experience will increasingly determine which therapies achieve broad adoption and preferred positioning within constrained reimbursement environments.

Leaders should view the current environment as an opportunity to accelerate investments in differentiated delivery formats, regional manufacturing, and outcome-focused engagements. Those that act decisively to align clinical development with commercial access imperatives and operational resilience will create defensible positioning in an increasingly complex global landscape.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Diabetes Drugs Market, by Drug Class

  • 8.1. Amylin Analogs
  • 8.2. GLP-1 Receptor Agonists
  • 8.3. Insulin
    • 8.3.1. Long Acting
    • 8.3.2. Short-Acting
  • 8.4. Oral Antidiabetic Drugs (OADs)

9. Diabetes Drugs Market, by Route Of Administration

  • 9.1. Inhalation
  • 9.2. Injectable
  • 9.3. Oral

10. Diabetes Drugs Market, by Diabetes Type

  • 10.1. Type 1 Diabetes
  • 10.2. Type 2 Diabetes

11. Diabetes Drugs Market, by Drug Origin

  • 11.1. Branded Drugs
  • 11.2. Generic Drugs

12. Diabetes Drugs Market, by Distribution Channel

  • 12.1. Home Healthcare
  • 12.2. Hospital Pharmacy
  • 12.3. Online Pharmacy
  • 12.4. Retail Pharmacy

13. Diabetes Drugs Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Diabetes Drugs Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Diabetes Drugs Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Diabetes Drugs Market

17. China Diabetes Drugs Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Astellas Pharma Inc
  • 18.6. AstraZeneca plc
  • 18.7. Bayer AG
  • 18.8. Biocon Limited
  • 18.9. Boehringer Ingelheim International GmbH
  • 18.10. Bristol Myers Squibb Company
  • 18.11. Cipla Limited
  • 18.12. Daiichi Sankyo Company Limited
  • 18.13. Eli Lilly and Company
  • 18.14. GlaxoSmithKline plc
  • 18.15. Johnson and Johnson
  • 18.16. Merck and Co Inc
  • 18.17. Novartis AG
  • 18.18. Novo Nordisk A S
  • 18.19. Pfizer Inc
  • 18.20. Roche Holding AG
  • 18.21. Sanofi S A
  • 18.22. Sun Pharmaceutical Industries Ltd
  • 18.23. Takeda Pharmaceutical Company Limited
  • 18.24. Teva Pharmaceutical Industries Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL DIABETES DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL DIABETES DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL DIABETES DRUGS MARKET SIZE, BY AMYLIN ANALOGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL DIABETES DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL DIABETES DRUGS MARKET SIZE, BY LONG ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL DIABETES DRUGS MARKET SIZE, BY SHORT-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL ANTIDIABETIC DRUGS (OADS), BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL DIABETES DRUGS MARKET SIZE, BY INHALATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL DIABETES DRUGS MARKET SIZE, BY INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL DIABETES DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL DIABETES DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL DIABETES DRUGS MARKET SIZE, BY BRANDED DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL DIABETES DRUGS MARKET SIZE, BY GENERIC DRUGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOME HEALTHCARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL DIABETES DRUGS MARKET SIZE, BY HOSPITAL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL DIABETES DRUGS MARKET SIZE, BY ONLINE PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL DIABETES DRUGS MARKET SIZE, BY RETAIL PHARMACY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL DIABETES DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 101. MIDDLE EAST DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. AFRICA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 108. AFRICA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 113. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 115. ASIA-PACIFIC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL DIABETES DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 120. ASEAN DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 121. ASEAN DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. ASEAN DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 123. ASEAN DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 124. GCC DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GCC DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 126. GCC DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 127. GCC DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 128. GCC DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. GCC DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 130. GCC DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPEAN UNION DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 138. BRICS DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 140. BRICS DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 141. BRICS DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. BRICS DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. BRICS DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 144. BRICS DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 145. G7 DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 146. G7 DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 147. G7 DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 148. G7 DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 149. G7 DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. G7 DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 151. G7 DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. NATO DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. NATO DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 154. NATO DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 155. NATO DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 156. NATO DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. NATO DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 158. NATO DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 159. GLOBAL DIABETES DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. UNITED STATES DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 161. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 162. UNITED STATES DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 163. UNITED STATES DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 166. UNITED STATES DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 167. CHINA DIABETES DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 168. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 169. CHINA DIABETES DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 170. CHINA DIABETES DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 171. CHINA DIABETES DRUGS MARKET SIZE, BY DIABETES TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. CHINA DIABETES DRUGS MARKET SIZE, BY DRUG ORIGIN, 2018-2032 (USD MILLION)
  • TABLE 173. CHINA DIABETES DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)